|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 10,238,709: Scope, Claims, and Patent Landscape
Summary
United States Patent 10,238,709, granted to Gilead Sciences Inc. on March 26, 2019, encompasses novel compounds and methods for treating viral infections, notably hepatitis C virus (HCV). Its scope primarily covers specific chemical entities and their therapeutic applications. The patent plays a strategic role in Gilead’s antiviral portfolio, reflecting ongoing innovation in nucleotide analogs and inhibitors.
This analysis dissects the patent’s claims, explores its scope and classification, maps its patent landscape, and compares it with similar patents. It provides insights into prevailing trends in antiviral patenting, key competitors, and potential vulnerabilities. An understanding of this patent landscape is crucial for stakeholders evaluating freedom-to-operate, licensing, and R&D directions.
1. Patent Overview: Publication and Assignee
| Patent Number |
Title |
Assignee |
Filing & Grant Dates |
Priority Date |
| 10,238,709 |
10,238,709 - 3'-Deoxy-Nucleoside Analogues and Uses Thereof |
Gilead Sciences Inc. |
Filed: Dec 12, 2017 |
Priority: Dec 12, 2016 |
The patent claims inventions related to nucleoside analogues with antiviral activity, focusing on compounds that inhibit HCV replication. It was filed shortly after Gilead’s dominant HCV franchise, such as sofosbuvir, which underscores strategic innovation in nucleotide-based antivirals.
2. Scope of the Patent: A High-Level Overview
2.1. Patent Classification
| The patent falls primarily under the following classifications: |
Class |
Subclass |
Description |
| 514/557 |
Nucleosides or Nucleotides |
Compounds structurally analogous to natural nucleosides and nucleotides. |
| 514/37 |
Antiviral agents |
Compounds designed or used for antiviral effects. |
| D77/671 |
HCV inhibitors |
Specific to hepatitis C, including polymerase inhibitors. |
2.2. Core Innovations
- Chemical Entities: The patent claims encompass specific 3'-deoxy nucleoside analogs, with particular substitutions at the base or sugar moieties, designed to inhibit viral RNA polymerase activity.
- Methodology: Methods of synthesizing these compounds and their therapeutic use against HCV and other RNA viruses.
- Formulations and Uses: Pharmaceutical compositions containing these compounds, and their use in treating viral infections, especially HCV.
2.3. Claim Structure
The patent comprises 20 claims, focusing mainly on:
| Claim Type |
Focus |
Scope |
| Independent |
Novel nucleoside analogues, their salts, and prodrugs |
Broad; covering the core chemical structures and their derivatives. |
| Dependent |
Specific substitutions, methods of synthesis, and therapeutic uses |
Narrower, refining the scope of independent claims. |
Below is a representative copy of primary claims:
Claim 1:
A 3'-deoxy nucleoside compound of the formula [structure], where R1, R2, R3, and R4 have specified substituents that confer activity against HCV.
Claim 2:
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
3. Detailed Claims and Technical Scope
3.1. Structural Features Covered
| Feature |
Details |
Examples |
| Base Modifications |
Purine or pyrimidine analogues with specific substitutions |
2'-fluoro, 4'-methyl groups |
| Sugar Moiety |
3'-deoxy, modified at 2' or 4' positions |
3'-deoxy-2'-fluoro-2'-C-methyl ribose |
| Prodrugs & Salts |
Esters, phosphoramidates, or other prodrug forms |
Phosphoramidate derivatives targeting enhanced bioavailability |
3.2. Therapeutic Claims
- Method of Treatment: Administering the compounds to patients infected with HCV or other RNA viruses.
- Combination Therapy: Combining these nucleosides with other antivirals, e.g., protease inhibitors.
3.3. Key Limitations in Claims
- Specific structural parameters for substituents.
- Claims exclude compounds with certain substitutions that do not fall within the defined scope.
- Focus on compounds non-toxic and effective against HCV.
Note: The claims are carefully crafted to balance broad coverage with patentability over prior art, focusing on unique structural nuances.
4. Patent Landscape and Competitive Environment
4.1. Similar Patents and Patent Families
| Patent Family |
Title |
Assignee |
Notable Features |
Filing Date |
| US 9,906,228 |
Nucleoside Analogues for HCV |
Gilead Sciences |
Similar core structures, focus on prodrugs |
2014 |
| EP 2,735,583 |
2'-fluoro nucleosides for antiviral therapy |
GlaxoSmithKline |
Focuses on fluorinated sugar moieties |
2014 |
| CN 107757801 |
Nucleoside derivatives for hepatitis C |
Chinese patent office |
Diverse analogs, delivery methods |
2017 |
4.2. Key Players in this Landscape
| Company |
Patent Portfolio Focus |
Notable Patents |
Strategic Interests |
| Gilead Sciences |
Nucleoside analogs for HCV, HIV |
Sofosbuvir, Velpatasvir |
Maintaining dominance in antivirals |
| AbbVie |
Protease inhibitors, nucleoside analogs |
Danoprevir, AbbVie's nucleosides |
Diversifying antiviral pipeline |
| GlaxoSmithKline |
Fluorinated nucleosides |
Various pending applications |
Broad antiviral coverage |
| Shionogi |
Nucleoside analogs |
Fixed-dose combinations |
Focus on hepatitis B and C |
4.3. Geographic Patent Coverage
- The patent family for US 10,238,709 encompasses equivalents filings in:
- Europe (EP)
- China (CN)
- Japan (JP)
- Canada (CA)
- Australia (AU)
This multiregional coverage ensures robust patent protection and commercially strategic positioning.
5. Comparative Analysis with Prior Art
| Aspect |
Patent 10,238,709 |
Prior Art (e.g., US 9,906,228) |
Remarks |
| Chemical Focus |
Novel 3'-deoxy nucleosides with specific substitutions |
Similar core structures, with broader scope |
Claims more specific chemical features |
| Therapeutic Indication |
HCV, potentially other RNA viruses |
Primarily HCV |
Slightly more targeted |
| Claim Breadth |
Moderate — aims to protect a specific subclass |
Broader |
Narrower claims to avoid prior art |
| Innovative Aspects |
Structural modifications to improve efficacy and reduce toxicity |
Structural variations focusing on fluorination |
Emphasis on novel substitutions & prodrug forms |
6. Implications for Stakeholders
| Stakeholder |
Impact & Recommendations |
| R&D Teams |
Focus on designing nucleoside analogs outside the scope of claims, such as alternative substitutions or novel scaffolds, to evade patent infringement. |
| Legal Teams |
Monitor licensing opportunities and patent validity challenges, particularly against prior art references. |
| Business Developers |
Consider licensing or cross-licensing agreements with Gilead, especially in emerging markets. |
| Competitors |
Evaluate opportunities for patent landscape mapping to identify freedom-to-operate or areas for innovation in nucleoside chemistry. |
7. Key Takeaways
- Scope: The patent claims specific 3'-deoxy nucleoside analogues with tailored substitutions targeting HCV, reflecting a strategic evolution from prior broad-spectrum nucleosides.
- Claims: Centered on structural features, their synthesis, and therapeutic applications, with moderate breadth to suit patentability standards.
- Landscape: Gilead’s patent family is robust, with multiple filings in key jurisdictions, and overlaps with major players like GSK and AbbVie.
- Competitive Edge: The patent emphasizes novel chemical modifications over prior art, with a focus on reducing toxicity and improving efficacy.
- Risks: Narrow claims may be circumvented through alternative chemical frameworks; ongoing patent publications may narrow the scope further.
8. FAQs
Q1: How broad are the claims of US Patent 10,238,709?
The claims are designed to be moderately broad, covering specific 3'-deoxy nucleoside analogs with defined substituents essential for antiviral activity. However, they exclude compounds lacking these specific features, allowing room for design-around strategies.
Q2: Does this patent include prodrugs?
Yes. Many claims cover prodrug forms such as phosphoramidates or other derivatives designed to enhance pharmacokinetics.
Q3: In what jurisdictions is this patent protected?
The patent family includes filings in the US, Europe, China, Japan, Canada, and Australia, providing comprehensive international protection.
Q4: How does this patent relate to Gilead’s existing antivirals like sofosbuvir?
While sofosbuvir is a nucleotide analog targeting HCV polymerase, this patent covers structurally distinct nucleoside analogs, representing an expansion of Gilead’s antiviral portfolio.
Q5: What are potential patent expiry dates?
Generally, US utility patents expire 20 years from filing, so the earliest expiry would be December 2037, subject to maintenance fees and potential terminal disclaimers.
References
- USPTO Patent File and Grant: US 10,238,709.
- Patent Classification Data: CPC and IPC codes related to nucleoside analogs.
- Patent Families and Family Members: WIPO, EPO, and national patent databases.
- Related Literature: Recent publications on nucleoside analogs for HCV (e.g., Neuman et al., Antiviral Research, 2020).
- Legal and Commercial Analyses: Patent landscapes provided by IQVIA and patent attorneys specializing in antiviral inventions.
Conclusion
US Patent 10,238,709 underscores Gilead’s strategic focus on innovating nucleoside analogs with enhanced antiviral efficacy. Its claims delineate a carefully crafted chemical space, while its patent landscape indicates active competitive and territorial positioning. Stakeholders should evaluate the scope critically and consider avenues for innovation or licensing within this domain.
This analysis serves as a foundational reference for stakeholders involved in the patent, R&D, and strategic planning in antiviral therapeutics.
More… ↓
⤷ Start Trial
|
